{
  "schema_version": "1.0",
  "last_updated": "2026-07-08",
  "guidelines": [
    {
      "body": "American Diabetes Association (ADA)",
      "topic": "Standards of Care in Diabetes",
      "relevance": "GLP-1 receptor agonists recommended for weight management and glycemic control in type 2 diabetes"
    },
    {
      "body": "American Association of Clinical Endocrinology (AACE)",
      "topic": "Obesity and diabetes management",
      "relevance": "Supports incretin-based therapies within comprehensive obesity care"
    },
    {
      "body": "American Society for Metabolic and Bariatric Surgery (ASMBS)",
      "topic": "Obesity treatment",
      "relevance": "Recognizes anti-obesity medications including GLP-1/GIP agonists as part of the treatment continuum"
    },
    {
      "body": "The Obesity Society (TOS)",
      "topic": "Evidence-based obesity treatment",
      "relevance": "Endorses pharmacotherapy for chronic obesity management"
    }
  ],
  "note": "Guideline references are provided for context. This site is not medical advice; consult a licensed clinician."
}